2019 CYIR Finalized

53 between the two groups. Comments 1. No difference in survival was observed between patients with treated brain metastases and not, although numbers assessed were low. 2. Older patients (>65) performed better. 3. Tumour mutational burden was not predictive of response. OTHER ARTICLES OF INTEREST Lopes G et al. Pembrolizumab (pembro) versus plati- num-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3, KEYNOTE-042 Study. Journal of Clinical Oncology 2018 36:18_suppl, LBA4-LBA4 Borghaei H et al. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. J Thorac Oncol 2019: 14(1):124-129 Papadimitrakopoulou V. A et al. IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/ Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC. Presented at: International Association for the Study of Lung Cancer’s (IASLC) 2018 World Conference on Lung Cancer (WCLC); 2018 Sept 23-26; Toronto, Ont, Canada. Abstract #OA05.07 Socinski MA et al. Atezolizumab for the first line treat- ment of metastatic non-squamous NSCLC. N Engl J Med 2018, 378(24):2288-2301 Cappuzzo et al. IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Presented at: ESMO congress; 2018 Oct 22; Munich, Germany Abstract # LBA 53 Paz-Ares L et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. N Engl J Med 2018; 379(21):2040-2051 Rizvi et al. Durvalumab with or without tremelimumab vs platinum based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. Presented at: ESMO Immuno-Oncology Congress, 2018 Dec 13; Geneva, Switzerland, Abstract LBA6 Nakamura A et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefi- tinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). Presented at: ASCO Annual Meeting; 2018 Jun 1-5; Chicago, IL Horn et al. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res 2018; 24(12):2771- 2779 Novello S et al. Alectinib versus chemotherapy in crizo- tinib-pretreated anaplastic lymphoma kinase (ALK)- positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol 2018; 29(6):1409-1416 Provencio-Pulla et al. Neoadjuvant chemo/immuno- therapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multi- center exploratory study. NADIM study-SLCG, 10.1200/ JCO.2018.36.15_suppl.8521 LUNG CANCER

RkJQdWJsaXNoZXIy MTM1ODMw